08 May '23
PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) (" Carisma " or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer,
07 Mar '23
Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023 Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs PHILADELPHIA, March 7, 2023 /PRNewswire/ -- 
Displaying 1 - 10 of 20